Glycolytic Enzyme Plays Role in Prostate Cancer Survival

This article originally appeared here.
Share this content:
Glycolytic Enzyme Plays Role in Prostate Cancer Survival
Glycolytic Enzyme Plays Role in Prostate Cancer Survival

(HealthDay News) – An enzyme that balances the use of glucose for energy generation with the synthesis of antioxidants is important for the growth and survival of prostate cancer, according to a study published online March 22 in Cancer Discovery.

Susana Ros, from Cancer Research UK London Research Institute, and colleagues examined the effect on survival of silencing the genes for 222 metabolic enzymes, transporters, and regulators in three metastatic prostate cancer cell lines compared with a nonmalignant prostate epithelial cell line.

The researchers identified several genes required for survival. One important gene in prostate cancer survival was the glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), which was required to maintain cellular redox balance. The expression of PFKFB4 messenger RNA was higher in metastatic prostate cancer than primary tumors. Depleting the expression of the gene in mice with prostate tumors inhibited tumor growth.

"Using an unbiased functional screen, we found that the glycolytic enzyme PFKFB4 is essential for prostate cancer cell survival by maintaining the balance between the use of glucose for energy generation and the synthesis of antioxidants," Ros and colleagues conclude. "Targeting PFKFB4 may therefore present new therapeutic opportunities."

One of the authors disclosed a financial tie to AstraZeneca.


Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs